Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

493

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

March 31, 2013

Conditions

Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative ColitisHepatitis A

Interventions

BIOLOGICAL

Epaxal Berna (virosomal hepatitis A vaccine)

standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.

Trial Locations (1)

Asan Medical Center, Seoul